Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine
| Autor: | M. Lelong, H. Wilczek, José M. Morales, G. Senatorski, Josep M. Grinyó, Anders Hartmann, N.V. Jamieson, James T. Burke, Rowan G. Walker, J.A. Scarola, Wolfgang Arns, A. Shoker, Yves Brault |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
medicine.medical_specialty Canada Adolescent Population Urology Renal function Blood Pressure Drug Administration Schedule chemistry.chemical_compound Young Adult Internal medicine Hyperlipidemia medicine Humans education Triglycerides Antibacterial agent Retrospective Studies Sirolimus Transplantation education.field_of_study medicine.diagnostic_test Dose-Response Relationship Drug business.industry Cholesterol Patient Selection Hypertriglyceridemia Cholesterol HDL Australia Cholesterol LDL medicine.disease Kidney Transplantation Lipids Europe Endocrinology Treatment Outcome chemistry Research Design Cyclosporine Surgery Drug Therapy Combination Lipid profile business Immunosuppressive Agents |
| Zdroj: | Transplantation proceedings. 41(6) |
| ISSN: | 1873-2623 |
| Popis: | Renal transplant recipients show an increased risk of cardiovascular disease compared with a nontransplant population. Herein we have shown an analysis of a randomized controlled trial wherein 525 patients receiving a first or second (9.7%) renal allograft from a deceased (89.1%), a living-related (7.8%), or a living-unrelated donor (3.1%) received sirolimus (SRL), cyclosporine (CsA), and steroids (ST) at the time of transplantation with randomization at 3 months after transplantation of 430 eligible patients to continue on SRL-CsA-ST or to have CsA withdrawn with increased SRL trough targets (SRL-ST group). Graft survival, patient survival, and renal function at 5 years were analyzed by average fasting total cholesterol (or=200 or200 mg/dL) and triglyceride (or=240 or240 mg/dL) subgroups. At 5 years, total, high-density lipoprotein (HDL), and low-density lipoprotein [LDL] cholesterol and triglyceride values were similar between the groups. Statins ( approximately 80% of patients of both groups) were most effective to lower cholesterol ( approximately 50 mg/dL; P.001; both groups), and fibrates ( approximately 25% of patients of both groups) were most effective to decrease triglycerides ( approximately 100 mg/dL; P.001; both groups). Renal function and blood pressure were significantly better with SRL-ST. Hypercholesterolemia and hypertriglyceridemia were associated with reduced graft survival, patient survival, and calculated GFR, but the only significant difference was lower graft survival among SRL-CsA-ST patients with hypertriglyceridemia. Cardiovascular-related deaths were reported in 3.7% and 2.8% of patients in the SRL-CsA-ST and SRL-ST groups, respectively. In conclusion, when compared with continuous SRL-CsA-ST, CsA withdrawal at 3 months followed by SRL-ST significantly improved glomerular filtration rate (GFR) and blood pressure without a further increase in lipid parameters or an incidence of untoward effects from hyperlipidemia, despite a 2-fold higher SRL exposure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect